EGFR mutations and clinical outcomes of chemotherapy for advanced non-small cell lung cancer: A meta-analysis

Lung Cancer

Volumn 85, Issue 3, 2014, Pages 339-345

  Zhang, Qiong ^a   Dai, Hong Hai ^a   Dong, Hong Yun ^b,c   Sun, Cheng Tao ^a   Yang, Zhe ^a   Han, Jun Qing ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c Wanhua Chemical Group Co Ltd   (China)

Author keywords

Chemotherapy; EGFR; Meta analysis; Mutation status; Non small cell lung cancer; Response rate

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR;

ASIAN; CANCER CHEMOTHERAPY; CAUCASIAN; COCHRANE LIBRARY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA SEQUENCE; EMBASE; GENE MUTATION; HUMAN; MEDLINE; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; MORTALITY; MUTATION; PATHOLOGY; PUBLISHING; RISK;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM STAGING; ODDS RATIO; PUBLICATION BIAS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84925456347     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.06.011     Document Type: Review

References (40)

1. Gao G., Ren S., Li A., Xu J., Xu Q., Su C., et al. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials. Int J Cancer 2012, 131:E822-E829.
2. Dahabreh I.J., Linardou H., Siannis F., Kosmidis P., Bafaloukos D., Murray S. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2010, 16:291-303.
3. Yang C-H., Yu C-J., Shih J-Y., Chang Y-C., Hu F-C., Tsai M-C., et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008, 26:2745-2753.
4. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
5. Gong W., Zhang X., Wu J., Chen L., Li L., Sun J., et al. RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. Lung Cancer 2012, 75:374-380.
6. Chen S., Zhang J., Wang R., Luo X., Chen H. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 2010, 70:63-70.
7. Han Y., Wang X., Xiao N., Liu Z.-D. mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in postoperative patients with non-small cell lung cancer. Asian Pac J Cancer Prev 2013, 14:2987-2990.
8. Guan J.L., Zhong W.Z., An S.J., Yang J.J., Su J., Chen Z.H., et al. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy. Ann Surg Oncol 2013, 20:1381-1388.
9. Wu S.G., Yang C.H., Yu C.J., Lee J.H., Hsu Y.C., Chang Y.L., et al. Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Lung Cancer 2011, 72:333-339.
10. Sordella R., Bell D.W., Haber D.A., Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305:1163-1167.
11. Yoshimasu T., Oura S., Ohta F., Hirai Y., Naito K., Nakamura R., et al. Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer. J Thorac Oncol 2011, 6:1658-1662.
12. Khambata-Ford S., Harbison C.T., Hart L.L., Awad M., Xu L.A., Horak C.E., et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:918-927.
13. Wu J.Y., Shih J.Y., Yang C.H., Chen K.Y., Ho C.C., Yu C.J., et al. Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer. Int J Cancer 2010, 126:247-255.
14. Lee J.O., Kim T.M., Lee S.H., Kim D.W., Kim S., Jeon Y.K., et al. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol 2011, 6:1474-1480.
15. Wells G., Shea B., O'connell D., Peterson J., Welch V., Losos M., et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2003.
16. Schoenleber S.J., Kurtz D.M., Talwalkar J.A., Roberts L.R., Gores G.J. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009, 100:1385-1392.
17. The Cochrane Collaborative Review Group on HIV Infection and AIDS Editorial Policy: Inclusion and Appraisal of Experimental and Non-experimental (Observational) Studies 2009.
18. Tierney J.F., Stewart L.A., Ghersi D., Burdett S., Sydes M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16.
19. Millett G.A., Flores S.A., Marks G., Reed J.B., Herbst J.H. Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men. J Am Med Assoc 2008, 300:1674-1684.
20. Yoshida K., Yatabe Y., Park J., Ogawa S., Park J.Y., Shimizu J., et al. Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations. J Cancer Res Clin Oncol 2010, 136:527-535.
21. Hotta K., Kiura K., Toyooka S., Takigawa N., Soh J., Fujiwara Y., et al. Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer. J Thorac Oncol 2007, 2:632-637.
22. Okamoto I., Aoe K., Kato T., Hosomi Y., Yokoyama A., Imamura F., et al. Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naive patients with advanced nonsquamous non-small-cell lung cancer. Invest New Drugs 2013, 31:1275-1282.
23. Kalikaki A., Koutsopoulos A., Hatzidaki D., Trypaki M., Kontopodis E., Stathopoulos E., et al. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer 2010, 69:110-115.
24. Lee J.K., Park H.S., Kim D.W., Kulig K., Kim T.M., Lee S.H., et al. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. Cancer 2012, 118:3579-3586.
25. Li F., Bai H., Li X., Wu M., Yu R., Shi A., et al. Role of EGFR mutation status in patients with stage III non-squamous non-small cell lung cancer treated with chemoradiotherapy. Zhongguo Fei Ai Za Zhi 2011, 14:715-718.
26. Bai H., Wang Z., Chen K., Zhao J., Lee J.J., Wang S., et al. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol 2012, 30:3077-3083.
27. Bakker E. Is the DNA sequence the gold standard in genetic testing? Quality of molecular genetic tests assessed. Clin Chem 2006, 52:557-558.
28. Qin L., Zhong W., Zhang L., Li L.Y., Wang M.Z. Comparison of three methods for detecting epidermal growth factor receptor mutations in plasma DNA samples of Chinese patients with advanced non-small cell lung cancer. Chin Med J (Engl) 2011, 124:887-891.
29. Cappuzzo F., Ligorio C., Toschi L., Rossi E., Trisolini R., Paioli D., et al. EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007, 2:423-429.
30. Park J.H., Lee S.H., Keam B., Kim T.M., Kim D.W., Yang S.C., et al. EGFR mutations as a predictive marker of cytotoxic chemotherapy. Lung Cancer 2012, 77:433-437.
31. Dong X., Zhao X., Hao Y., Wei Y., Yin Q., Du J. Response to first-line chemotherapy in patients with non-small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status. Clin Lung Cancer 2013, 14:680-687.
32. Campos-Parra A.D., Zuloaga C., Manriquez M.E., Aviles A., Borbolla-Escoboza J., Cardona A., et al. KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. Am J Clin Oncol 2013, [Epub ahead of print].
33. Zhuo M.L., Wu M.N., Zhao J., Song S.W., Bai H., Wang S.H., et al. Epidermal growth factor receptor genotype in plasma DNA and outcome of chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Chin Med J (Engl) 2011, 124:3510-3514.
34. Lin C.C., Hsu H.H., Sun C.T., Shih J.Y., Lin Z.Z., Yu C.J., et al. Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors. J Thorac Oncol 2010, 5:1424-1429.
35. Lee K.H., Han S.W., Hwang P.G., Oh D.Y., Kim D.W., Chung D.H., et al. Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer. Jpn J Clin Oncol 2006, 36:344-350.
36. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23:5900-5909.
37. Bell D.W., Lynch T.J., Haserlat S.M., Harris P.L., Okimoto R.A., Brannigan B.W., et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005, 23:8081-8092.
38. Camidge D.R., Kono S.A., Lu X., Okuyama S., Baron A.E., Oton A.B., et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 2011, 6:774-780.
39. Douillard J.Y., Shepherd F.A., Hirsh V., Mok T., Socinski M.A., Gervais R., et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010, 28:744-752.
40. Wu M., Zhao J., Song S.W., Zhuo M., Wang X., Bai H., et al. EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer 2010, 67:343-347.